secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2025-12-02T23:59:59+00:00
Accession:  0001104659-25-117697
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec PEDMARK Phase 2/3 Japan trial meets endpoint; hearing loss reduced to 16-24% vs 56-63% historical
--------------------------------------------------------------------------------

- Primary endpoint met: hearing loss in 24% (ASHA) and 16% (Brock) of evaluable patients vs 56-63% historically.
- Tumor response rate ~95%, showing PEDMARK does not interfere with cisplatin antitumor activity.
- Company plans to pursue registration in Japan and explore partnering or licensing opportunities.
- Study enrolled 27 patients aged 3-18 years in primary cohort; PEDMARK well-tolerated with no attributed adverse events.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465925117697/0001104659-25-117697-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465925117697/tm2532518d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-117697

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer